Related Experiment Video

Updated: Jul 6, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Lupus anticoagulant syndrome: a case report

Tara Khan1, Olivia Lopez, Robert Birkhahn

  • 1Department of Emergency Medicine, New York Methodist Hospital, Brooklyn, New York 11215, USA.

The Journal of Emergency Medicine
|April 9, 2008
PubMed

Insights

Deep vein thrombosis (DVT) can stem from hypercoagulable states like antiphospholipid antibody syndrome (APS). Recognizing and treating thrombotic events in APS patients is crucial for effective management.

Area of Science:

  • Hematology
  • Immunology
  • Vascular Medicine

Background:

  • Deep vein thrombosis (DVT) requires physician familiarity for recognition and management.
  • Hypercoagulable states are significant contributors to DVT development, particularly in upper extremities.
  • Antiphospholipid antibody syndrome (APS) is a hypercoagulable state characterized by autoantibodies against anionic phospholipid complexes.

Observation:

  • In vivo, APS autoantibodies induce a hypercoagulable state via proposed mechanisms.
  • In vitro, these antibodies inhibit coagulation by interfering with phospholipid complex assembly, prolonging clotting times.
  • Patients with APS present a paradox: appearing anticoagulated in vitro but existing in a pro-thrombotic state.

Findings:

  • APS patients are in a pro-thrombotic state despite in vitro anticoagulation.
  • Effective management requires anticoagulants such as heparin and warfarin.
  • This discussion emphasizes recognizing and treating thrombotic events within the context of APS.

Implications:

  • Enhanced understanding of APS is vital for accurate diagnosis and treatment of thrombosis.
  • Physicians must consider APS in patients with unexplained or recurrent thrombotic events.
  • Timely and appropriate anticoagulation therapy is essential for managing APS-related thrombotic risks.

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...